BG66112B1 - Подобрени фармацевтични състави - Google Patents

Подобрени фармацевтични състави

Info

Publication number
BG66112B1
BG66112B1 BG106976A BG10697602A BG66112B1 BG 66112 B1 BG66112 B1 BG 66112B1 BG 106976 A BG106976 A BG 106976A BG 10697602 A BG10697602 A BG 10697602A BG 66112 B1 BG66112 B1 BG 66112B1
Authority
BG
Bulgaria
Prior art keywords
pharmaceutical formulations
improved pharmaceutical
improved
mixture
pharmaceutically acceptable
Prior art date
Application number
BG106976A
Other languages
English (en)
Other versions
BG106976A (bg
Inventor
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23936923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG66112(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG106976A publication Critical patent/BG106976A/bg
Publication of BG66112B1 publication Critical patent/BG66112B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Изобретението се отнася до подобрени фармацевтични форми, съдържащи едно или повече разтворими съединения, инхибиращи HIV протеаза, с подобрени свойства на разтворимост в мастна киселина с дълга или средна верига, или смес от тях, фармацевтично приемлив алкохол и вода.
BG106976A 2000-01-19 2002-08-02 Подобрени фармацевтични състави BG66112B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48773900A 2000-01-19 2000-01-19
PCT/US2000/032771 WO2001052821A1 (en) 2000-01-19 2000-12-01 Improved pharmaceutical formulations

Publications (2)

Publication Number Publication Date
BG106976A BG106976A (bg) 2003-05-30
BG66112B1 true BG66112B1 (bg) 2011-05-31

Family

ID=23936923

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106976A BG66112B1 (bg) 2000-01-19 2002-08-02 Подобрени фармацевтични състави

Country Status (26)

Country Link
EP (3) EP2269591B1 (bg)
JP (1) JP4769400B2 (bg)
KR (1) KR100861885B1 (bg)
CN (1) CN100536833C (bg)
AT (1) ATE395049T1 (bg)
AU (2) AU1940501A (bg)
BG (1) BG66112B1 (bg)
BR (1) BR0011864A (bg)
CA (1) CA2395987C (bg)
CY (3) CY1108197T1 (bg)
CZ (1) CZ304118B6 (bg)
DE (1) DE60038899D1 (bg)
DK (3) DK1248600T3 (bg)
ES (3) ES2676151T3 (bg)
HK (1) HK1120213A1 (bg)
HU (1) HU229778B1 (bg)
IL (2) IL150265A0 (bg)
MX (1) MXPA02007097A (bg)
NO (1) NO331400B1 (bg)
NZ (1) NZ519724A (bg)
PT (3) PT2269591T (bg)
SI (3) SI1248600T1 (bg)
SK (1) SK287143B6 (bg)
TR (1) TR201809435T4 (bg)
WO (1) WO2001052821A1 (bg)
ZA (1) ZA200205109B (bg)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767429B2 (ja) 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB0615211D0 (en) * 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
WO2009019661A1 (en) * 2007-08-07 2009-02-12 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0541168A1 (en) * 1991-11-08 1993-05-12 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
WO1995007696A1 (en) * 1993-09-13 1995-03-23 Abbott Laboratories Pharmaceutical composition of hiv-protease inhibitors
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484801A (en) * 1994-01-28 1996-01-16 Abbott Laboratories Pharmaceutical composition for inhibiting HIV protease
US5541206A (en) * 1989-05-23 1996-07-30 Abbott Laboratories Retroviral protease inhibiting compounds
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594836A (en) * 1897-11-30 Corner-brace
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
ATE296625T1 (de) 1990-11-19 2005-06-15 Monsanto Co Retrovirusprotease inhibitoren
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0765873B1 (en) 1991-10-11 2002-04-17 Dupont Pharmaceuticals Company Cyclic ureas and analogues useful as retroviral protease inhibitors
ES2066623T3 (es) 1992-03-13 1995-03-01 Bio Mega Boehringer Ingelheim Derivados sustituidos del acido pipecolinico como inhibidores de la vih-proteasa.
EP0641333B1 (en) 1992-05-20 1996-08-14 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
KR100360964B1 (ko) 1992-12-29 2002-11-22 아보트 러보러터리즈 레트로바이러스성 프로테아제 억제 화합물의 중간체의제조방법
AU7518694A (en) 1993-08-20 1995-03-21 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP1295874A3 (en) * 1995-12-13 2003-04-02 Abbott Laboratories Retroviral protease inhibiting compounds
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
SI1183026T1 (sl) * 1999-06-04 2006-10-31 Abbott Lab Izboljsane farmacevtske spojine, vsebujoce ritonavir

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541206A (en) * 1989-05-23 1996-07-30 Abbott Laboratories Retroviral protease inhibiting compounds
EP0541168A1 (en) * 1991-11-08 1993-05-12 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
WO1995007696A1 (en) * 1993-09-13 1995-03-23 Abbott Laboratories Pharmaceutical composition of hiv-protease inhibitors
US5725878A (en) * 1993-09-13 1998-03-10 Abbott Laboratories Pharmaceutical composition comprising HIV protease inhibiting compounds
US5484801A (en) * 1994-01-28 1996-01-16 Abbott Laboratories Pharmaceutical composition for inhibiting HIV protease
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound

Also Published As

Publication number Publication date
PL361396A1 (en) 2004-10-04
NZ519724A (en) 2004-07-30
CY1120408T1 (el) 2019-07-10
IL150265A0 (en) 2002-12-01
SI1917958T1 (sl) 2012-10-30
CA2395987C (en) 2009-12-22
HUP0302070A2 (hu) 2003-09-29
ES2387579T3 (es) 2012-09-26
CN1424907A (zh) 2003-06-18
TR201809435T4 (tr) 2018-07-23
HUP0302070A3 (en) 2007-02-28
SK11102002A3 (sk) 2002-12-03
CZ304118B6 (cs) 2013-11-06
EP1917958A2 (en) 2008-05-07
DK1248600T3 (da) 2008-09-08
ES2676151T3 (es) 2018-07-17
HK1120213A1 (en) 2009-03-27
CN100536833C (zh) 2009-09-09
SI1248600T1 (sl) 2008-08-31
PT1917958E (pt) 2012-08-16
NO20023455L (no) 2002-09-18
NO20023455D0 (no) 2002-07-18
DK2269591T3 (en) 2018-07-16
CY1108197T1 (el) 2014-02-12
AU2006235895B2 (en) 2009-08-13
SK287143B6 (sk) 2010-01-07
EP2269591A2 (en) 2011-01-05
KR20020082210A (ko) 2002-10-30
CA2395987A1 (en) 2001-07-26
CY1112995T1 (el) 2016-04-13
EP1248600A1 (en) 2002-10-16
PT2269591T (pt) 2018-07-09
HU229778B1 (hu) 2014-07-28
EP2269591B1 (en) 2018-04-04
PT1248600E (pt) 2008-08-25
ZA200205109B (en) 2003-10-31
EP1917958B1 (en) 2012-06-13
BR0011864A (pt) 2004-07-20
KR100861885B1 (ko) 2008-10-09
SI2269591T1 (en) 2018-08-31
JP4769400B2 (ja) 2011-09-07
EP1917958A3 (en) 2008-08-27
MXPA02007097A (es) 2003-01-28
AU1940501A (en) 2001-07-31
DK1917958T3 (da) 2012-09-24
WO2001052821A1 (en) 2001-07-26
CZ20022663A3 (cs) 2002-11-13
IL150265A (en) 2015-02-26
ATE395049T1 (de) 2008-05-15
AU2006235895A1 (en) 2006-11-30
DE60038899D1 (de) 2008-06-26
ES2304990T3 (es) 2008-11-01
EP1248600B1 (en) 2008-05-14
EP2269591A3 (en) 2011-07-27
BG106976A (bg) 2003-05-30
JP2003533435A (ja) 2003-11-11
NO331400B1 (no) 2011-12-19

Similar Documents

Publication Publication Date Title
CY1105237T1 (el) Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir
CY1120408T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
BR9911160A (pt) Ciclosporinas
EE05382B1 (et) MandelhappeÁderivaadid,ÁnendeÁvalmistamiseÁmeetod,ÁnendeÁkasutamineÁtrombiiniÁinhibiitoritenaÁjaÁneidÁsisaldavadÁravimkoostised
UY27320A1 (es) Nuevas composiciones farmacéuticas
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
HUP0401811A2 (hu) Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
EA200300481A1 (ru) Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов
DE60031886D1 (de) Purinderivate
DE69819539D1 (de) Antithrombotische mittel
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
HN2001000021A (es) Nuevos derivados de amidas heterociclicas
ECSP045086A (es) Composiciones farmaceuticas que contienen macrolidos
MA26966A1 (fr) Nouveaux composes utilisables en tant qu'inhibiteurs de protease hiv
WO2001095890A3 (en) Oral pharmaceutical compositions containing terbinafine